On the evening of December 31, Gan & Lee Pharmaceuticals announced the dismissal of its Chief Financial Officer and Vice President, Sun Cheng, citing strategic needs for the globalization upgrade of its innovative drug R&D, marketing, and investment financing businesses. The termination of his relevant positions is effective from the date of approval by the board of directors. Following his departure, Sun Cheng will no longer hold any position within the company; his originally scheduled term was set to expire on May 20, 2028.
According to available information, Sun Cheng, born in 1979, is a Certified Practising Accountant (Australia) and holds a master's degree from Tsinghua University. From 2003 to 2010, he was employed at KPMG Huazhen LLP, serving as an Audit Manager. Between 2010 and 2018, he worked at Asia America Gas Holdings Limited (HK2686) as the Chief Financial Officer. From 2018 to 2020, he held the position of General Manager of the Finance Center at Beijing Sunshine Sea & Sky Parking Management Co., Ltd.
Starting in 2020, Mr. Sun served as Vice President and Chief Financial Officer of Gan & Lee Pharmaceuticals. He also held concurrent positions as a director of Gan & Lee Shandong and Beijing Gangan, and as the General Manager and Financial Controller of Gan & Lee Shanghai and Gan & Lee Holdings (Hong Kong).
Regarding compensation, data from Gan & Lee's 2024 annual report shows that Sun Cheng's remuneration was 694,900 yuan. The company's announcement also indicated that the board has approved the appointment of Ms. Zhou Li to act as the company's Chief Financial Officer on an interim basis.
On the performance front, on October 30, Gan & Lee Pharmaceuticals released its report for the third quarter of 2025. The company reported operating revenue of 3.05 billion yuan, a year-on-year increase of 35.7%. Net profit attributable to shareholders of the parent company reached 818 million yuan, surging 61.3% compared to the same period last year. After deducting non-recurring gains and losses, the net profit was 692 million yuan, marking a substantial increase of 122.8%.
The report mentioned that growth in the sales volume of the company's insulin preparation products in the domestic market contributed to the rise in operating revenue. Furthermore, the company has further consolidated its market share internationally by optimizing product quality and customer service.
Comments